Today, the SVP of Cel-Sci Corp (CVM), Daniel Zimmerman, sold shares of CVM for $7,248.
See today’s analyst top recommended stocks >>
Based on Cel-Sci Corp’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $197.4K and GAAP net loss of $14.93 million. In comparison, last year the company earned revenue of $113.9K and had a GAAP net loss of $6.19 million. The Company has a Price to Book ratio of 95666.6667. Currently, Cel-Sci Corp has an average volume of 260.3K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS).
